Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status

[1]  J. Pignon,et al.  Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  J. Tabernero,et al.  Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  E. Van Cutsem,et al.  Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials , 2017, JAMA oncology.

[4]  G. Prager,et al.  Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  R. Bernards,et al.  Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. , 2016, Cancer research.

[6]  J Ricke,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  P. Laurent-Puig,et al.  Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial. , 2016, JAMA oncology.

[8]  Y. Kitagawa,et al.  The Worse Prognosis of Right-Sided Compared with Left-Sided Colon Cancers: a Systematic Review and Meta-analysis , 2016, Journal of Gastrointestinal Surgery.

[9]  G. Fontanini,et al.  FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. , 2015, The Lancet. Oncology.

[10]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[11]  Marc Peeters,et al.  Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer , 2015, Clinical Cancer Research.

[12]  G. Fontanini,et al.  BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  B. Massuti,et al.  First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. , 2015, European journal of cancer.

[14]  F. Pontén,et al.  High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort , 2015, PloS one.

[15]  J. Douillard,et al.  Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status , 2015, Drugs.

[16]  U. Martens,et al.  Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies , 2015, Langenbeck's Archives of Surgery.

[17]  Hartmut Link,et al.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[18]  S. Kopetz,et al.  Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. , 2014, Clinical colorectal cancer.

[19]  J. Hecht,et al.  PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Tournigand,et al.  Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study , 2014, Health and Quality of Life Outcomes.

[21]  E. Van Cutsem,et al.  Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). , 2014 .

[22]  J. Douillard,et al.  RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.

[23]  J. Tabernero,et al.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.

[24]  A. Lièvre,et al.  The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011. , 2013, European journal of cancer.

[25]  John D Potter,et al.  BRAF Mutation Status and Survival after Colorectal Cancer Diagnosis According to Patient and Tumor Characteristics , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[26]  J. Aerts,et al.  A final analysis from the CHOICE study examining darbepoetin alfa use for chemotherapy-induced anaemia in current European clinical practice , 2012, Current medical research and opinion.

[27]  C. Tournigand,et al.  Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. , 2011, The oncologist.

[28]  V. Baracos,et al.  Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer , 2011, British Journal of Cancer.

[29]  Josep Tabernero,et al.  Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  E. Van Cutsem,et al.  Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  A. Bardelli,et al.  Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  C. Bokemeyer,et al.  Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial , 2009, BMC Cancer.

[33]  T. Nagykálnai,et al.  [Chemotherapy of elderly patients with colorectal cancer]. , 2009, Magyar onkologia.

[34]  L. Mazzucchelli,et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  W. Scheithauer,et al.  Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  C. Bokemeyer,et al.  Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  R. Stephens,et al.  Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Susan Quinn,et al.  Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer , 2008, Clinical Cancer Research.

[39]  E. Van Cutsem,et al.  Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. , 2008, European journal of cancer.

[40]  D. Sargent,et al.  Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  A. Carrato,et al.  Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. , 2007, European journal of cancer.

[42]  R. Labianca,et al.  Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. , 2007, Journal of the National Cancer Institute.

[43]  W. Scheithauer,et al.  Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  F. Lordick,et al.  Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  C. Köhne,et al.  Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. , 2007, Cancer treatment and research.

[46]  H. Kestler,et al.  Matrix-comparative genomic hybridization from multicenter formalin-fixed paraffin-embedded colorectal cancer tissue blocks , 2007, BMC Cancer.

[47]  C. Köhne.  Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? Against the proposal. , 2006, The Lancet. Oncology.

[48]  T. Seufferlein,et al.  Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  C. Köhne,et al.  On prejudice and facts and choices. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  K. Van Steen,et al.  Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? , 2006, European journal of cancer.

[51]  C. Köhne,et al.  Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells , 2006, Cancer Immunology, Immunotherapy.

[52]  C. Köhne,et al.  Drug Insight: metastatic colorectal cancer—oral fluoropyrimidines and new perspectives in the adjuvant setting , 2005, Nature Clinical Practice Oncology.

[53]  C. Köhne,et al.  Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  C. Bokemeyer,et al.  Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  H. Cohen,et al.  Never too old? Age should not be a barrier to enrollment in cancer clinical trials. , 2005, The oncologist.

[56]  Medicina Nei Secoli La Redazione.  No Abstract Available , 2005 .

[57]  W. Scheithauer,et al.  Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  H. Gschaidmeier,et al.  Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[59]  J. Braess,et al.  Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cells. , 2004, Annals of hematology.

[60]  C. Köhne,et al.  Current perspectives in the treatment of metastatic colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[61]  C. Bokemeyer,et al.  Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study , 2003, British Journal of Cancer.

[62]  W. Scheithauer,et al.  Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  M. Ducreux,et al.  Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial , 2003, British Journal of Cancer.

[64]  M. Ducreux,et al.  Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[65]  C. Köhne,et al.  Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment , 2003, Cancer Chemotherapy and Pharmacology.

[66]  C. Köhne,et al.  Combined chemotherapy trials require combined pharmacogenetic approaches. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  W. Scheithauer,et al.  Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  B. Dörken,et al.  The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines , 2002, Oncogene.

[69]  C. Köhne.  [Capsule instead of infusion--new oral chemotherapy option]. , 2002, Krankenpflege Journal.

[70]  C. Köhne,et al.  Phase II study of weekly 24-hour intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver metastases from colorectal carcinomas. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[71]  M. Buyse,et al.  Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer , 2001, British Journal of Cancer.

[72]  C. Köhne,et al.  Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[73]  B. Dörken,et al.  Anatomical Variations in the Internal Jugular Veins of Cancer Patients Affecting Central Venous Access , 2001, Ultraschall in der Medizin.

[74]  C. Köhne,et al.  High-dose etoposide phosphate and G-CSF mobilizes peripheral blood stem cells in patients that previously failed to mobilize , 2001, Annals of Hematology.

[75]  B. Dörken,et al.  Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil plus Folinic Acid in Combination with Mitomycin C for the Treatment of Advanced Gastric Cancer , 2000, Oncology.

[76]  B. Nordlinger,et al.  Regional chemotherapy in the treatment of advanced pancreatic cancer--is it relevant? , 2000, European journal of cancer.

[77]  E. Van Cutsem,et al.  Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies. , 1999, Anti-cancer drugs.

[78]  C. Köhne,et al.  Relevance of neoadjuvant and adjuvant treatment for patients with resectable liver metastases of colorectal carcinoma , 1999, Langenbeck's Archives of Surgery.

[79]  B. Dörken,et al.  Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  C. Köhne,et al.  Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  R. Herrmann,et al.  Colorectal cancer liver metastasis: local treatment for a systemic disease? , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[82]  A. Ganser,et al.  Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study , 1998, BMJ.

[83]  C. Bokemeyer,et al.  Is Continuous 24-Hour Infusion of 5-Fluorouracil plus High-Dose Folinic Acid Effective in Patients with Progressive or Recurrent Colorectal Cancer? , 1998, Oncology.

[84]  M. Friedrich,et al.  Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity. , 1998, British Journal of Cancer.

[85]  W. Hiddemann,et al.  Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  C. Köhne,et al.  A Pilot Study on Intensive Weekly 24-Hour Intra-Arterial Infusion with 5-Fluorouracil and Folinic Acid for Colorectal Liver Metastases , 1997, Oncology.

[87]  W. Hiddemann,et al.  Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study. , 1997, European journal of cancer.

[88]  W. Hiddemann,et al.  Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[89]  C. Köhne,et al.  [After-care of colorectal carcinoma--value of tumor markers]. , 1997, Der Internist.

[90]  B. Dörken,et al.  The Value of Weekly High Dose Infusional 5-Fluorouracil in the Treatment of Advanced Colorectal Cancer , 1997, Tumori.

[91]  W. Hiddemann,et al.  Phase II evaluation of 5-fluourouracil plus folinic acid and alpha 2b-interferon in metastatic colorectal cancer. , 1997, Oncology.

[92]  D. Kerr,et al.  Is intra-arterial chemotherapy worthwhile in the treatment of patients with unresectable hepatic colorectal cancer metastases? , 1996, European journal of cancer.

[93]  C. Köhne,et al.  The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer. , 1996, The Journal of infusional chemotherapy.

[94]  W. Hiddemann,et al.  Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  H. Rauschecker,et al.  Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.